TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:35
Moleculin Biotech Inc. ( MBRX ) https://www.moleculin.com
4.68USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-67.15%
MBRX
SPY
32.74%
-91.85%
MBRX
SPY
92.93%
-93.58%
MBRX
SPY
224.41%
MBRX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
14.77
-8.20
0.09
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.60
1617.75
0.57
-13.77
0.00
0.31
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.8348
-51.44
-56.63
1.76
Other Earnings and Cash Flow Stats:
Moleculin Biotech Inc. ( MBRX ) Net Income TTM ($MM) is -27.22
Moleculin Biotech Inc. ( MBRX ) Operating Income TTM ($MM) is -30.43
Moleculin Biotech Inc. ( MBRX ) Owners' Earnings Annual ($MM) is -26.07
Moleculin Biotech Inc. ( MBRX ) Current Price to Owners' Earnings ratio is -0.40
Moleculin Biotech Inc. ( MBRX ) EBITDA TTM ($MM) is -30.31
Moleculin Biotech Inc. ( MBRX ) EBITDA Margin is 0.00%
Capital Allocation:
Moleculin Biotech Inc. ( MBRX ) has paid 0.00 dividends per share and bought back 26.376881 million shares in the past 12 months
Moleculin Biotech Inc. ( MBRX ) has increased its debt by 0.133 million USD in the last 12 months
Capital Structure:
Moleculin Biotech Inc. ( MBRX ) Interest-bearing Debt ($MM) as of last quarter is 0
Moleculin Biotech Inc. ( MBRX ) Annual Working Capital Investments ($MM) are -4
Moleculin Biotech Inc. ( MBRX ) Book Value ($MM) as of last quarter is 26
Moleculin Biotech Inc. ( MBRX ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Moleculin Biotech Inc. ( MBRX ) has 23 million in cash on hand as of last quarter
Moleculin Biotech Inc. ( MBRX ) has 6 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Moleculin Biotech Inc. ( MBRX ) has 2 common shares outstanding as of last quarter
Moleculin Biotech Inc. ( MBRX ) has 0 million USD of preferred stock value
Academic Scores:
Moleculin Biotech Inc. ( MBRX ) Altman Z-Score is -5.78 as of last quarter
Moleculin Biotech Inc. ( MBRX ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Moleculin Biotech Inc. ( MBRX ) largest shareholder is Wells Fargo & Co owning 717 shares at 0.00 ($MM) value
Walter V Klemp(an insider) Bought 188404 shares of Moleculin Biotech Inc. ( MBRX ) for the amount of $129998.76 on 2023-12-26
3.21% of Moleculin Biotech Inc. ( MBRX ) is held by insiders, and 7.25% is held by institutions
Moleculin Biotech Inc. ( MBRX ) went public on 2016-06-02
Other Moleculin Biotech Inc. ( MBRX ) financial metrics:
FCF:-28.53
Unlevered Free Cash Flow:-19.31
EPS:-10.07
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-86.05
Beta:1.76
Buffet's Owners Earnings:-26.07
Price to Owner's Earnings:-0.40
About Moleculin Biotech Inc. ( MBRX ) :
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/tranion modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.